

having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R₁ is -R'OR''' wherein R' is C₁-C₅ straight or branched chain alkyl and R''' is hydrogen or C₁-C₅ alkyl;

G is -OR₂ wherein R₂ is C₁-C₅ straight or branched chain alkyl; and


R₃ is C₁-C₁₂ straight or branched chain alkyl.

b1
b2

6. (amended) [A] The pharmaceutical composition for treating, preventing, or managing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune diseases comprising as an active ingredient a therapeutically effective amount of a compound of claim 1.

7. (amended) [A] The pharmaceutical composition of claim 6 further comprising a pharmaceutically acceptable diluent or carrier.

17. (amended) A CB2 specific agonist comprising a compound of the general formula:



having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R₁ is -R'OR''' wherein R' is C₁-C₅ straight or branched chain alkyl and R''' is hydrogen or C₁-C₅ alkyl;

b3 b4

G is -OR₂ wherein R₂ is C₁-C₅ straight or branched chain alkyl; and
R₃ is C₁-C₁₂ straight or branched chain alkyl.

Please add the following new claims:

18. The agonist of claim 17, wherein R₃ is a straight chain or branched -C₅-C₉ alkyl.
19. The agonist of claim 17, wherein R₃ is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.
20. The agonist of claim 17, wherein R₁ is -CH₂OH, G is -OCH₃, and R₃ is 1,1-dimethyl heptyl.
21. The agonist of claim 20, wherein the dotted line represents a double bond.
22. A pharmaceutical composition for treating, preventing, or managing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune diseases comprising as an active ingredient a therapeutically effective amount of the CB2 specific agonist of claim 17.
23. A pharmaceutical composition of claim 22, further comprising a pharmaceutically acceptable diluent or carrier.
24. The pharmaceutical composition of claim 22, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution or emulsion prepared with natural or synthetic ionic or non-ionic surfactants, or a combination of such cosolvent and micellar or emulsion solutions.
25. The pharmaceutical composition of claim 6, wherein R₃ is a straight chain or branched -C₅-C₉ alkyl.
26. The pharmaceutical composition of claim 6, wherein R₃ is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.